MRE-269
MRE-269 (ACT-333679) is the long-acting, orally active metabolite of Selexipag and a potent prostacyclin receptor (IP receptor) agonist. It is utilized in pulmonary arterial hypertension (PAH) research, with studies demonstrating its efficacy in both in vitro assays and in vivo animal models of pulmonary hypertension.
Product Specifications
CAS Number
475085-57-5
Product Name Alternative
ACT 333679, ACT-333679, ACT333679, MRE 269, MRE269, MRE-269, inhibit, Inhibitor, ProstaglandinReceptor, prostaglandin I2 receptor, Prostaglandin Receptor
Field of Research
Immunology & Inflammation, Pharmacology & Drug Discovery
Purity
98.25% (May vary between batches)
Solubility
DMSO:55 mg/mL (131.1 mM) ;10% DMSO+90% Corn Oil:2.5 mg/mL (5.96 mM)
Smiles
N (CCCCOCC (O) =O) (C (C) C) C=1N=C (C (=NC1) C2=CC=CC=C2) C3=CC=CC=C3
Molecular Formula
C25H29N3O3
Molecular Weight
419.52
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
A09658-Dylight488 100 µg
Anti-NANP Antibody Picoband® (Dylight488 Conjugate)
Sign In for Pricing
View Details 
![Cytochrome p450 2J2 (CYP2J2) Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI5C9]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
TA503482AM 100 µL
Cytochrome p450 2J2 (CYP2J2) Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI5C9]
Sign In for Pricing
View Details